BETNOVATE CREAM 0.1% ww

Țară: Singapore

Limbă: engleză

Sursă: HSA (Health Sciences Authority)

Ingredient activ:

BETAMETHASONE VALERATE EQV BETAMETHASONE

Disponibil de la:

GLAXOSMITHKLINE PTE LTD

Codul ATC:

D07AC01

Dozare:

0.1% w/w

Forma farmaceutică:

CREAM

Compoziție:

BETAMETHASONE VALERATE EQV BETAMETHASONE 0.1% w/w

Calea de administrare:

TOPICAL

Tip de prescriptie medicala:

Prescription Only

Produs de:

GLAXO WELLCOME OPERATIONS

Statutul autorizaţiei:

ACTIVE

Data de autorizare:

1995-07-06

Prospect

BETNOVATE
TM 
BETAMETHASONE 17-VALERATE 

Betamethasone valerate is referred to as
‘Betnovate’ throughout this information.

PRESENTATION 
_BETNOVATE_ CREAM (NON-GREASY BASE) 
0.1% betamethasone as 17-valerate in a water-miscible cream base 

CLINICAL PARTICULARS 

INDICATIONS 

-  Eczema including atopic, infantile, and discoid eczemas 
- Prurigo 
nodularis 
-  Psoriasis (excluding widespread plaque psoriasis) 
-  Neurodermatoses including lichen simplex, lichen planus 
- Seborrhoeic 
dermatitis 
- Contact 
sensitivity 
reactions 
- Discoid 
lupus 
erythematosus 
-  An adjunct to systemic steroid therapy in generalised
erythroderma 
-  Insect bite reactions 
- Prickly 
heat 

DOSAGE AND ADMINISTRATION 

A small quantity should be applied to the affected area two or
three times daily until 
improvement occurs. It may then be possible to maintain
improvement by applying once a 
day, or even less often. 

_BETNOVATE_ creams are especially appropriate for
moist or weeping surfaces and 
_BETNOVATE_ ointments for dry, lichenified or scaly lesions, but
this is not invariably so.  

In the more resistant lesions, such as the thickened
plaques of psoriasis on elbows and 
knees, the effect of _BETNOVATE_ can be enhanced, if
necessary, by occluding the treatment 
area with polythene film. Overnight occlusion only is
usually adequate to bring about a 
satisfactory response in such
lesions thereafter, improvement can usually be maintained by 
regular application without occlusion. 

CHILDREN 

_BETNOVATE_ is contraindicated in children under
one year of age.  

Children are more likely to develop local and
systemic side effects of topical corticosteroids 
and, in general, require shorter courses and less
potent agents than adults.  

Care
should be taken when using _BETNOVATE_ to ensure the amount
applied is the 
minimum�

Caracteristicilor produsului

BETNOVATE
BETAMETHASONE 17-VALERATE
Betamethasone valerate is referred to as ‘
_BETNOVATE’_
throughout this information.
PRESENTATION
_BETNOVATE_ CREAM (NON-GREASY BASE)
0.1% betamethasone as 17-valerate in a water-miscible cream base
CLINICAL INFORMATION
INDICATIONS
-
Eczema including atopic, infantile, and discoid eczemas
-
Prurigo nodularis
-
Psoriasis (excluding widespread plaque psoriasis)
-
Neurodermatoses including lichen simplex, lichen planus
-
Seborrhoeic dermatitis
-
Contact sensitivity reactions
-
Discoid lupus erythematosus
-
An adjunct to systemic steroid therapy in generalised erythroderma
-
Insect bite reactions
-
Prickly heat
DOSAGE AND ADMINISTRATION
A small quantity should be applied to the affected area two or three
times daily until
improvement occurs. It may then be possible to maintain improvement by
applying once a
day, or even less often.
_BETNOVATE_
creams
are
especially
appropriate
for
moist
or
weeping
surfaces
and
_BETNOVATE_
ointments for dry, lichenified or scaly lesions, but this is not
invariably so.
In the more resistant lesions, such as the thickened plaques of
psoriasis on elbows and knees,
the effect of
_BETNOVATE_
can be enhanced, if necessary, by occluding the treatment area
with polythene film. Overnight occlusion only is usually adequate to
bring about a satisfactory
response in such lesions thereafter, improvement can usually be
maintained by regular
application without occlusion.
CHILDREN
_BETNOVATE_
is contraindicated in children under one year of age.
Children are more likely to develop local and systemic side effects of
topical corticosteroids
and, in general, require shorter courses and less potent agents than
adults.
Care should be taken when using
_BETNOVATE_
to ensure the amount applied is the minimum
that provides therapeutic benefit.
ELDERLY
The greater frequency of decreased hepatic or renal function in the
elderly may delay
elimination if systemic absorption occurs. Therefore the minimum
quantity should be used
for the shortest duration to achieve the desir